$JNJ News

Johnson & Johnson (JNJ) Faces Fresh Talc Risk After $45 Million Verdict Stands

Illinois Appellate Court Affirms $45 Million Mesothelioma Verdict Against Johnson & Johnson and Kenvue

B of A Securities Maintains Neutral on Johnson & Johnson, Raises Price Target to $263

Johnson & Johnson (JNJ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”

J&J wins FDA approval for dual-energy ablation catheter

Dual-Energy EP Catheter Approval Could Be A Game Changer For Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

Morgan Stanley Maintains Overweight on Johnson & Johnson, Raises Price Target to $284

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Citigroup Maintains Buy on Johnson & Johnson, Raises Price Target to $298

Johnson & Johnson Receives FDA Approval For Its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Platform

Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism

Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update

Unusual Put Option Activity in Johnson & Johnson After JNJ Stock's Recent Runup

Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now

J&J's MedTech Segment Eyes Another Strong Quarter in Q2

Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

NAVN, JNJ, CRWD Stocks Hit 52-Week Highs Last Week: What's Driving The Surge?